| scholarly article | Q13442814 |
| P2093 | author name string | Eric E Swayze | |
| Michael E Østergaard | |||
| Punit P Seth | |||
| Ruchi Gupta | |||
| Hans J Gaus | |||
| Alfred E Chappell | |||
| P2860 | cites work | Structural Insights into High Density Lipoprotein: Old Models and New Facts | Q26770434 |
| The 1.8-A crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin | Q27652320 | ||
| Structure of the haptoglobin-haemoglobin complex | Q27682043 | ||
| Hemopexin: structure, function, and regulation | Q28202032 | ||
| Structure to function relationships in ceruloplasmin: a 'moonlighting' protein | Q28215383 | ||
| Shotgun proteomics: tools for the analysis of complex biological systems | Q28215896 | ||
| The human plasma proteome: history, character, and diagnostic prospects | Q28218148 | ||
| Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. | Q51794680 | ||
| The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions. | Q55259593 | ||
| Structural Determinants for the Interactions of Chemically Modified Nucleic Acids with the Stabilin-2 Clearance Receptor. | Q55375711 | ||
| Autorosette Inhibition Factor: Isolation and Properties of the Human Plasma Protein | Q71002014 | ||
| C1q: A fresh look upon an old molecule | Q39364237 | ||
| TricycloDNA-modified oligo-2'-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry. | Q39370899 | ||
| Fluorescence polarization assays in high-throughput screening and drug discovery: a review | Q41467248 | ||
| Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion | Q42618432 | ||
| Affinity chromatography, two-dimensional electrophoresis, adapted immunodepletion and mass spectrometry used for detection of porcine and piscine heparin-binding human plasma proteins | Q43972755 | ||
| Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals | Q46087257 | ||
| Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide | Q46605294 | ||
| Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes | Q47120143 | ||
| Novel mechanisms and functions of complement. | Q47396517 | ||
| The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays | Q47761810 | ||
| Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo | Q50061759 | ||
| Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver | Q50100050 | ||
| Association between the plasma proteome and plasma α-tocopherol concentrations in humans. | Q51348188 | ||
| Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. | Q51743392 | ||
| Proteomics by mass spectrometry: approaches, advances, and applications | Q28243072 | ||
| Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma | Q28296528 | ||
| Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG) | Q28594971 | ||
| Effects of DNA sequence and structure on binding of RecA to single-stranded DNA. | Q33929695 | ||
| Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery | Q34011941 | ||
| Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms | Q34025149 | ||
| Structure of apolipoprotein B-100 in low density lipoproteins. | Q34087902 | ||
| Factor V and thrombotic disease: description of a janus-faced protein | Q34123469 | ||
| Serpin structure, function and dysfunction | Q34202797 | ||
| IgG subclasses and allotypes: from structure to effector functions | Q34368678 | ||
| Apolipoprotein E: From lipid transport to neurobiology | Q34497951 | ||
| Tweaking the structure to radically change the function: the evolution of transthyretin from 5-hydroxyisourate hydrolase to triiodothyronine distributor to thyroxine distributor | Q35072295 | ||
| Physicochemical properties of phosphorothioate oligodeoxynucleotides | Q36000544 | ||
| Fibrinogen and fibrin structure and functions | Q36230901 | ||
| Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver | Q36775577 | ||
| SERPINA3 (aka alpha-1-antichymotrypsin). | Q36813610 | ||
| DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing | Q37031903 | ||
| Dynamic structure of plasma fibronectin | Q37057966 | ||
| Sequence-dependent elasticity and electrostatics of single-stranded DNA: signatures of base-stacking. | Q37621959 | ||
| β(2) -Glycoprotein I: evolution, structure and function. | Q37871051 | ||
| X-ray structures of transferrins and related proteins | Q37920198 | ||
| Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein (HDL): protein conformational ensemble on HDL. | Q38013180 | ||
| New insights into the structure and function of the plasminogen/plasmin system. | Q38164155 | ||
| Demystifying heparan sulfate-protein interactions. | Q38194193 | ||
| Phosphorothioates, essential components of therapeutic oligonucleotides | Q38263580 | ||
| Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice | Q38290824 | ||
| Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes | Q38292185 | ||
| Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice. | Q38293019 | ||
| Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes. | Q38293581 | ||
| Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides | Q38301148 | ||
| Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. | Q38303249 | ||
| Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). | Q38312483 | ||
| Complement factor H in host defense and immune evasion. | Q39036058 | ||
| Cellular uptake and trafficking of antisense oligonucleotides | Q39154516 | ||
| Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials | Q39354204 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 1110-1122 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Nucleic Acids Research | Q135122 |
| P1476 | title | Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay | |
| P478 | volume | 47 |
| Q98386176 | Advances in oligonucleotide drug delivery |
| Q91932549 | Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates |
| Q104130342 | Efficient Gene Suppression by DNA/DNA Double-Stranded Oligonucleotide In Vivo |
| Q92283429 | Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle |
| Q92865460 | Highly efficient silencing of microRNA by heteroduplex oligonucleotides |
| Q90391306 | Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice |
| Q89805468 | Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement |
| Q91604440 | Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins |
| Q92933262 | Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides |
Search more.